Current AD therapystrategies primarily depend on the inhibitionof AChE to increase ACh levels., However, with the progressionof AD, AChE activity decreases and BChE activity increases.−,  Therefore, dual inhibitors that simultaneously inhibit AChE andBChE are of great interest since single-target cholinesterase inhibitorsmay not provide optimal efficacy. This evidence concerns the gene ACHE and Alzheimer disease.